Iovance Biotherapeutics Inc
NASDAQ:IOVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
US |
|
Reckitt Benckiser Group PLC
LSE:RKT
|
UK |
|
Technip Energies NV
LSE:0A8A
|
FR |
|
Sollensys Corp
OTC:SOLS
|
US |
|
FormFactor Inc
NASDAQ:FORM
|
US |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
US |
|
P
|
Pernod Ricard SA
XBER:PER
|
FR |
|
C
|
Compass Digital Acquisition Corp
NASDAQ:CDAQ
|
KY |
|
Vale SA
BOVESPA:VALE3
|
BR |
|
Seven & i Holdings Co Ltd
TSE:3382
|
JP |
|
China Vanke Co Ltd
F:18V0
|
CN |
|
Gateley (Holdings) PLC
F:5I2
|
UK |
|
C
|
CITIC Securities Co Ltd
SWB:CI9
|
CN |
Wall St Price Targets
IOVA Price Targets Summary
Iovance Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
IOVA is 8.613 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IOVA's stock price target?
Price Target
8.613
USD
According to Wall Street analysts, the average 1-year price target for
IOVA is 8.613 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.
What is the Revenue forecast for Iovance Biotherapeutics Inc?
Projected CAGR
28%
The compound annual growth rate for Revenue over the next 8 years is 28%.